Connecticut Senate Approves Expansion of Psychedelic Therapy Pilot Program for Adults

The Connecticut Senate has unanimously passed legislation to broaden the state's pioneering psychedelic-assisted therapy pilot program, positioning the state ahead of anticipated federal approval of substances like psilocybin and MDMA. The bill, sponsored by the Joint Committee on Public Health, cleared the Senate with a 35-0 vote and now moves to the House of Representatives for further consideration. If enacted, the measure will expand access beyond military veterans and first responders to include any adult over 18 who meets clinical eligibility criteria established by the administering medical school’s institutional review board

Under the proposed changes, the existing statute governing the pilot program would be repealed and replaced. The new framework would allow qualified adults to participate in clinical settings where researchers can study the efficacy of psychedelic therapies for conditions such as refractory depression and post-traumatic stress disorder (PTSD). Importantly, the legislation removes the sunset provision that would have ended the program upon federal approval of psilocybin or MDMA, ensuring the initiative can continue regardless of federal scheduling changes

The bill requires the state Department of Mental Health and Addiction Services to establish the psychedelic-assisted therapy pilot program within available appropriations, to be administered by a Connecticut medical school. According to the proposal, "qualified patients" would receive MDMA- or psilocybin-assisted therapy as part of an FDA-approved research program. By striking outdated deadlines and expanding eligibility, lawmakers aim to accelerate research and access for those with treatment-resistant mental health conditions

State legislators underscored the urgent need for alternative therapies in their remarks. "For far too long, the people in our state who are going through refractory depression and post-traumatic stress disorder, they have tried various treatments to be able to help them," said Sen. Saud Anwar, chair of the Public Health Committee. "Unfortunately, there are not a lot of options that are available in those situations, and we have seen a lot of individuals hurt themselves and then commit suicide." Sen. Heather Somers added, "I think that we owe it to those living with trauma—especially those who have served our country, who are first responders, who have served us in many different ways—that we explore every safe and effective option."

Connecticut’s progressive approach to psychedelics comes amid ongoing legislative efforts to reform drug policy in the state. Last year, the House approved a psilocybin decriminalization bill, although it fell short in the Senate, and the governor’s support remains uncertain. Additionally, a 2022 budget bill included provisions for psychedelic therapy access, and lawmakers are currently considering expanded access to medical marijuana in healthcare facilities

From the OG Lab newsroom perspective, Connecticut’s legislative momentum reflects growing recognition of the potential benefits of psychedelic-assisted therapy, particularly for populations with limited treatment options. As research advances and regulatory landscapes evolve, the state’s expanded pilot program could serve as a model for other jurisdictions considering similar reforms. Industry stakeholders will be watching closely to see how the proposed changes impact patient outcomes and future federal policy alignment